NEW YORK (GenomeWeb News) – Agilent Technologies today said it will collaborate with Cell Line Genetics to develop high-throughput, genomic characterization workflows for confirming and monitoring the integrity of cell lines for translational and regenerative medicine research.

The workflows will be based on Agilent's CGH+SNP microarrays and SureFISH technologies. The arrays will be used to detect amplifications, deletions, and cell line clonality, while the FISH assays will be used to confirm aberrations "identified down to the single-cell level," said Agilent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.